Cipla Overview
- Year Founded
-
1935
- Status
-
Public
- Employees
-
40,993
- Stock Symbol
-
500087
- Investments
-
38
- Share Price
-
$17.14
- (As of Thursday Closing)
Cipla General Information
Description
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
Contact Information
Website
www.cipla.comCorporate Office
- Cipla House, Peninsula Business Park
- Ganpatrao Kadam Marg, Lower Parel
- Mumbai, Maharashtra 400013
- India
Corporate Office
- Cipla House, Peninsula Business Park
- Ganpatrao Kadam Marg, Lower Parel
- Mumbai, Maharashtra 400013
- India
Cipla Stock Performance
As of 22-May-2025, Cipla’s stock price is $17.14. Its current market cap is $13.8B with 808M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $17.14 | $17.33 | $15.32 - $20.28 | $13.8B | 808M | 54.3K | $0.77 |
Cipla Financials Summary
As of 31-Mar-2025, Cipla has a trailing 12-month revenue of $3.21B.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 |
|---|---|---|---|---|
| EV | 12,637,880 | 12,637,880 | 13,755,972 | 8,345,207 |
| Revenue | 3,210,428 | 3,210,428 | 3,073,790 | 2,798,728 |
| EBITDA | 944,933 | 944,933 | 826,566 | 621,419 |
| Net Income | 623,570 | 623,570 | 497,857 | 348,940 |
| Total Assets | 4,370,744 | 4,370,744 | 3,923,306 | 3,588,663 |
| Total Debt | 51,227 | 51,227 | 67,081 | 97,821 |
Cipla Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cipla Comparisons
Industry
Financing
Details
Cipla Competitors (52)
One of Cipla’s 52 competitors is Torrent Pharmaceuticals, a Corporation company based in Ahmedabad, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Torrent Pharmaceuticals | Corporation | Ahmedabad, India | ||||
| Alkem Laboratories | Formerly PE-Backed | Mumbai, India | ||||
| Glenmark Pharmaceuticals | Corporation | Mumbai, India | ||||
| Mankind Pharma | Formerly PE-Backed | New Delhi, India | ||||
| Lupin | Corporation | Mumbai, India |
Cipla Patents
Cipla Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023323642-A1 | A pharmaceutical composition of salbutamol and pharmaceutical green propellant | Pending | 10-Aug-2022 | ||
| CA-211320-S | Inhaler device | Active | 29-Dec-2021 | ||
| EP-4384525-A1 | Solid state forms of relugolix | Pending | 15-Sep-2021 | ||
| US-20240287090-A1 | Solid state forms of relugolix | Pending | 15-Sep-2021 | ||
| EP-4271366-A1 | Long acting injectable compositions of cariprazine or its pharmaceutically acceptable salts | Pending | 16-Mar-2021 | A61K31/495 |
Cipla Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cipla Investments & Acquisitions (38)
Cipla’s most recent deal was a Secondary Transaction - Private with Cipla (Jiangsu) Pharmaceuticals for . The deal was made on 25-Oct-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cipla (Jiangsu) Pharmaceuticals | 25-Oct-2024 | Secondary Transaction - Private | Pharmaceuticals | ||
| Sahajanand Medical Technologies | 15-Oct-2024 | Merger/Acquisition | Surgical Devices | ||
| GoApptiv | 01-Oct-2024 | Later Stage VC | Enterprise Systems (Healthcare) | ||
| Ethris | 18-Jun-2024 | Later Stage VC | Drug Discovery | ||
| GoApptiv | 15-Dec-2023 | Later Stage VC | Enterprise Systems (Healthcare) |
Cipla ESG
Risk Overview
Risk Rating
Updated December, 25, 2024
25.51 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Pharmaceuticals
Industry
of 843
Rank
Percentile
Pharmaceuticals
Subindustry
of 419
Rank
Percentile
Cipla Exits (8)
Cipla’s most recent exit was on 15-Jun-2023 from Wellthy Therapeutics. The exit was categorized as with 18 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Wellthy Therapeutics | 15-Jun-2023 | Completed |
|
||
| Wellthy Therapeutics | 09-Mar-2019 | Completed |
|
||
| Anmarate | 12-Apr-2017 | Completed |
|
||
| Quality Chemical Industries | 22-May-2015 | Completed |
|
||
| Saba Investment | 01-Jan-2014 | Merger/Acquisition | Completed |
|
Cipla Affiliates
Subsidiaries (4)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Cipla (Jiangsu) Pharmaceuticals | China | 2019 | |
| Cipla New Ventures | Mumbai, India | 2013 | |
| Cipla Medpro South Africa | Bellville, South Africa | 1935 | |
| Cipla EU | Addlestone, United Kingdom |
Cipla FAQs
-
When was Cipla founded?
Cipla was founded in 1935.
-
Where is Cipla headquartered?
Cipla is headquartered in Mumbai, India.
-
What is the size of Cipla?
Cipla has 40,993 total employees.
-
What industry is Cipla in?
Cipla’s primary industry is Pharmaceuticals.
-
Is Cipla a private or public company?
Cipla is a Public company.
-
What is Cipla’s stock symbol?
The ticker symbol for Cipla is 500087.
-
What is the current stock price of Cipla?
As of 22-May-2025 the stock price of Cipla is $17.14.
-
What is the current market cap of Cipla?
The current market capitalization of Cipla is $13.8B.
-
What is Cipla’s current revenue?
The trailing twelve month revenue for Cipla is $3.21B.
-
Who are Cipla’s competitors?
Torrent Pharmaceuticals, Alkem Laboratories, Glenmark Pharmaceuticals, Mankind Pharma, and Lupin are some of the 52 competitors of Cipla.
-
What is Cipla’s annual earnings per share (EPS)?
Cipla’s EPS for 12 months was $0.77.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
